Patientory
A blockchain-based platform for secure health data management, analytics, and incentivized patient engagement.
Website: https://patientory.com/
Cover Block
PUBLIC
| Name | Patientory |
| Tagline | A blockchain-based platform for secure health data management, analytics, and incentivized patient engagement. |
| Headquarters | Atlanta, United States |
| Founded | 2015 |
| Stage | Series A |
| Business Model | B2B2C |
| Industry | Healthtech |
| Technology | Blockchain / Web3 |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Undisclosed |
| Total Disclosed Funding | $9.38M (estimated) [Dealroom.co, 2026] |
Links
PUBLIC
- Website: https://patientory.com/
- LinkedIn: https://www.linkedin.com/company/patientory
- App Store: https://apps.apple.com/us/app/patientory/id1247860428
- Google Play: https://play.google.com/store/apps/details?id=com.patientory.mobile&hl=en_US&gl=US
Executive Summary
PUBLIC Patientory is a health data management company using blockchain to create a secure, patient-owned data ecosystem, a proposition that has attracted strategic capital from pharmaceutical giants and venture funds despite a decade-long, complex funding history. Founded in 2015 by Chrissa McFarlane, the company was born from a frustration with fragmented patient records and has evolved from a token-centric concept into a compliance-first enterprise SaaS model [Hypepotamus, 2026]. Its core offering is a dual-platform approach: a consumer-facing mobile wallet for patients to control and monetize their health data, and the Neith enterprise platform, which provides healthcare organizations with analytics for population health and AI-driven clinical trial recruitment [World Economic Forum, 2022].
McFarlane brings over a decade of healthcare technology experience and significant industry credibility, having been recognized as a Forbes Top 50 Woman in Tech and serving in leadership roles with HIMSS [Halcyon]. The company's investor list includes notable strategic names like Novartis and GSK, alongside venture firms such as Gener8tor and R/GA Ventures, with a total of $9.38 million raised across at least 13 discrete funding rounds according to the most comprehensive source [Dealroom.co, 2026]. The business model now targets recurring enterprise contracts with insurers, employers, and healthcare providers, a pivot evidenced by an active pilot in South Korea projected to generate an estimated $150,000 to $250,000 in annual recurring revenue [koreatechdesk.com, 2026].
Over the next 12-18 months, the critical watchpoints are the successful scaling of the Korean enterprise pilot, the conversion of other insurer and employer pilots into multi-year contracts, and the company's ability to maintain a clear strategic focus while managing its dual B2B2C go-to-market motion.
Data Accuracy: YELLOW -- Core product claims and founder background are well-sourced; funding history is corroborated by Dealroom.co but shows significant variance across other aggregators.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series A |
| Business Model | B2B2C |
| Industry / Vertical | Healthtech |
| Technology Type | Blockchain / Web3 |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Undisclosed |
Company Overview
PUBLIC
Patientory Inc. was founded in December 2015 by Chrissa McFarlane, an entrepreneur whose early experience in healthcare consulting revealed the persistent problem of fragmented and inaccessible patient data [Patientory Blog, 2018] [MM+M, 2018]. The company is headquartered in Atlanta, Georgia, and was incorporated as a for-profit entity, Patientory, Inc. [Crunchbase] [LinkedIn]. Its founding narrative centers on a mission to democratize health data ownership, a concept that was novel in the mid-2010s, predating widespread discussion of consumer health data rights.
Key operational milestones trace a path from concept to a maturing enterprise platform. The company joined the StartUp Health accelerator in 2016, gaining early ecosystem validation [StartUp Health, May 2021]. A significant technical milestone was the development and launch of its proprietary blockchain network, the PTOYMatrix, which it describes as a secure health information exchange and storage network [PTOY.org] [PranaChain, 2025]. By 2018, Patientory was engaging with industry standards bodies, with founder Chrissa McFarlane serving as co-chair of the HIMSS Blockchain Workgroup [HPN Online].
The company's business model has evolved notably over time. Initially focused on a token-centric, web3 narrative with its $PTOY cryptocurrency, Patientory has publicly shifted toward a compliance-first, enterprise SaaS model with recurring contracts and insurer pilots [Hypepotamus, 2026]. This strategic pivot is underscored by its recent global expansion, including a confirmed enterprise pilot in South Korea projected to onboard over 1,000 users in 2026 [koreatechdesk.com, 2026].
Data Accuracy: GREEN -- Company founding and HQ confirmed by Crunchbase and LinkedIn; strategic milestones and model evolution corroborated by multiple independent reports.
Product and Technology
MIXED Patientory's product architecture is a dual-platform structure, anchored by a proprietary blockchain network. The consumer-facing Patientory mobile app functions as a personal health data wallet, allowing users to store, track, and exchange their health records with medical professionals [World Economic Forum, 2022]. The app integrates lifestyle tracking features, such as a water intake monitor and photo diary, and uses AI to provide health insights and a personalized care plan [Patientory] [StartUp Health, May 2021]. A core engagement mechanism is an incentive system where users can earn rewards for healthy behaviors and for sharing anonymized data within the platform's Health Data Marketplace [Patientory] [StartUp Health, May 2021]. The enterprise counterpart, Neith, is a data management and analytics platform for healthcare organizations. It aggregates siloed clinical, lifestyle, and social determinants of health data to provide population health analytics and support AI-driven clinical trial recruitment [MIT Solve, 2022] [World Economic Forum, 2022]. The company lists its target enterprise buyers as health insurers, self-insured employers, pharmaceutical research organizations, and federally qualified health centers [Patientory Blog].
The underlying technology enabling this data exchange is the PTOYMatrix, a private, permissioned blockchain network described as a Health Information Exchange and storage layer [Patientory Association, 2026] [PTOY.org]. The network uses a native utility token, $PTOY, to facilitate transactions, reward node hosts, and enable in-app purchases [PTOY.org]. According to the company, this architecture is designed to ensure data is encrypted, tamper-proof, and under user-controlled consent, while reducing reliance on third-party intermediaries for data transactions [PTOY.org] [businessmodelcanvastemplate.com, 2026]. A recent strategic shift, reported in 2026, has seen Patientory move from a token-centric narrative to a compliance-first enterprise SaaS model, emphasizing recurring contracts, insurer pilots, and enhanced API infrastructure for multi-AI platform compatibility [Hypepotamus, 2026]. This evolution is exemplified by the CareGLP affiliate program, a weight management telemedicine service that combines GLP-1 medications with video coaching, powered by a third-party platform [Patientory, 2026] [Instagram, 2024].
Data Accuracy: GREEN -- Product claims and technical architecture are consistently described across the company website, World Economic Forum, MIT Solve, and recent press coverage [Hypepotamus, 2026].
Market Research
PUBLIC The market for secure, interoperable health data platforms is expanding beyond a compliance checkbox into a core infrastructure layer for value-based care and clinical research, a shift that validates the need for architectures that can reconcile patient ownership with enterprise analytics.
Total addressable market figures for blockchain in healthcare specifically are not consistently published, but analogous sizing for the broader health data interoperability and analytics sector provides context. A 2022 report by Grand View Research estimated the global healthcare data analytics market at $35.7 billion, projected to grow at a compound annual rate of 21.4% through 2030 [Grand View Research, 2022]. The clinical trial management software market, a key adjacent segment for Patientory's Neith platform, was valued at $1.8 billion in 2023 by Global Market Insights [Global Market Insights, 2023]. These figures suggest a substantial and growing SAM for platforms that can aggregate and analyze siloed health data, though the portion of that market willing to adopt a blockchain-based approach remains a smaller, more speculative SOM.
Demand is driven by several converging tailwinds. The push for value-based care models requires longitudinal patient data across settings to manage population health and measure outcomes [World Economic Forum, 2022]. Simultaneously, life sciences companies face increasing pressure to accelerate clinical trial timelines and improve participant diversity, creating demand for tools that can pre-screen and match patients using integrated real-world data [MIT Solve, 2022]. On the consumer side, growing awareness of data privacy and ownership, partly fueled by regulations like GDPR and CCPA, is creating a receptive audience for tools that offer control and potential monetization of personal health information [Center for a Digital Future, 2023].
Regulatory and macro forces are a double-edged sword. Regulations like the 21st Century Cures Act in the U.S. mandate greater data interoperability and patient access, which structurally benefits platforms like Patientory [Hypepotamus, 2026]. However, the healthcare sector's inherent conservatism regarding new technology, combined with stringent data security and privacy requirements (HIPAA, GDPR), creates a high barrier to adoption. The company's reported pivot to a "compliance-first, enterprise SaaS model" directly addresses this friction point [Hypepotamus, 2026]. Geopolitical factors, such as differing data sovereignty laws, also influence expansion strategies, as seen in Patientory's targeted entry into South Korea, a market with advanced digital health infrastructure and stated government support for health data innovation [koreatechdesk.com, 2026].
Healthcare Data Analytics (2022) | 35.7 | $B
Clinical Trial Management Software (2023) | 1.8 | $B
The chart illustrates the scale of the broader markets Patientory's solutions intersect with. The significant size of the data analytics segment underscores the enterprise appetite for insights, while the more niche but critical clinical trial software market represents a targeted beachhead for the Neith platform's AI recruitment capabilities.
Data Accuracy: YELLOW -- Market sizing figures are cited from third-party analyst reports, but the application to Patientory's specific blockchain-based wedge is an analyst inference. Tailwinds and regulatory drivers are corroborated by multiple public sources.
Competitive Landscape
MIXED Patientory operates in a crowded field of health data interoperability and patient engagement, but its positioning as a blockchain-native platform for both consumer data ownership and enterprise analytics creates a distinct, albeit complex, competitive map.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Patientory | Blockchain-based platform for secure health data management, analytics, and incentivized patient engagement. | Series A / $9.38M across 13 rounds (estimated) [Dealroom.co, 2026] | Dual B2B2C model with a proprietary blockchain network (PTOYMatrix) and a native token ($PTOY) for ecosystem incentives. | [World Economic Forum, 2022] |
| Redox | Cloud-based API network for healthcare data interoperability. | Venture-backed / $169.5M raised [Crunchbase] | Pure-play enterprise middleware; connects applications to EHR systems (Epic, Cerner) without a consumer-facing product or blockchain layer. | [Competitor] |
| Health Gorilla | Health information network and API platform for clinical data exchange. | Series B / $50M raised [Crunchbase] | Focuses on aggregating clinical data from labs, HIEs, and EHRs for providers and payers, with a strong emphasis on regulatory compliance (HIPAA, USCDI). | [Competitor] |
The competitive landscape fragments into three primary segments. In enterprise data interoperability, Patientory's Neith platform contends with well-funded API specialists like Redox and Health Gorilla, which have established extensive EHR integrations and significant venture backing. In the consumer health data wallet space, it faces direct competition from blockchain-focused peers like Medicalchain, as well as adjacent pressure from large tech platforms (Apple Health) and EHR patient portals. A third, adjacent segment includes clinical trial recruitment and population health analytics tools, where Patientory's AI-driven features compete with specialized SaaS vendors that do not use blockchain.
Patientory's defensible edge today rests on its integrated architecture and early regulatory positioning. The proprietary PTOYMatrix blockchain network is a technical differentiator that underpins both the consumer wallet's data sovereignty claims and the enterprise platform's audit trail [PTOY.org]. Founder Chrissa McFarlane's deep involvement with healthcare interoperability standards bodies, including HIMSS committees, provides regulatory and ecosystem credibility that pure-tech API players may lack [HPN Online]. However, this edge is perishable. The blockchain narrative in healthcare has cooled in favor of pragmatic, compliance-first SaaS, a shift Patientory itself has acknowledged [Hypepotamus, 2026]. The durability of its advantage depends on translating the blockchain architecture into tangible enterprise cost savings or novel revenue streams, like its data marketplace, faster than competitors can replicate its incentive models without the technical overhead.
The company is most exposed in two areas. First, in core enterprise interoperability, it lacks the reported scale of funding and integration depth of a Redox, which has publicly documented connections to hundreds of healthcare organizations. Second, the consumer-facing wallet and token economy face significant adoption hurdles against ubiquitous, free alternatives. A competitor like Health Gorilla, which is explicitly building a "token-less" health information network focused on standardized clinical data, represents a direct challenge to the necessity of a native cryptocurrency for health data exchange.
The most plausible 18-month scenario is one of continued segmentation. The winner will be the company that most effectively converts a technological wedge into a dominant commercial channel. For Patientory, winning looks like its Korean enterprise pilot scaling to a multi-million dollar ARR contract, proving that its combined analytics and patient engagement platform can be sold as a unified solution to insurers and health systems [koreatechdesk.com, 2026]. The loser in this segment would be a pure-play blockchain wallet like Medicalchain that fails to secure analogous enterprise pilots and remains confined to a niche consumer proposition. Patientory's hybrid model gives it more paths to revenue, but also demands it succeed on two competitive fronts simultaneously.
Data Accuracy: YELLOW -- Competitor profiles and funding are drawn from public databases; Patientory's differentiation claims are sourced from its own materials and ecosystem profiles.
Opportunity
PUBLIC
If Patientory successfully executes on its pivot from a token-centric narrative to a compliance-first enterprise platform, it could become the default infrastructure for patient-consented health data exchange and analytics, unlocking a multi-billion dollar opportunity in population health management and clinical research.
The headline opportunity is to establish the PTOYMatrix as the de facto, blockchain-enabled health information exchange (HIE) network for enterprises. This outcome is reachable because the company has already moved beyond conceptual validation, securing enterprise pilots with insurers and health systems, including a projected pilot in South Korea set to onboard over 1,000 users [koreatechdesk.com, 2026]. The core proposition,a secure, interoperable network that gives patients control while providing enterprises with unified, actionable data,addresses a persistent, multi-trillion dollar inefficiency in healthcare. The company's involvement with standard-setting bodies, such as the HIMSS Interoperability & Health Information Exchange Committee where founder Chrissa McFarlane serves [HPN Online], lends credibility to its ambition to shape, rather than just participate in, the future data architecture of healthcare.
The path to this scale is not singular. Several concrete growth scenarios could propel the company forward, each supported by early signals in its operational history.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Enterprise SaaS Dominance | Neith becomes the preferred population health analytics platform for self-insured employers and regional payers in the U.S. | A major reference customer, such as a named health plan, publicly deploys Neith for member risk stratification and care management. | The company has confirmed a shift to a "compliance-first, enterprise SaaS model with recurring contracts and insurer pilots" [Hypepotamus, 2026], indicating product-market fit is being actively pursued in this segment. |
| Clinical Research Infrastructure | The platform becomes a standard tool for patient recruitment and data management in decentralized clinical trials (DCTs). | A partnership with a top-10 pharmaceutical company or CRO (Contract Research Organization) to use Neith for a specific therapeutic area trial. | Patientory's solution is already positioned for "AI-driven clinical trial recruitment management" by MIT Solve [MIT Solve, 2022], and investors include life science giants Novartis and GSK [Tracxn, 2026]. |
| APAC Expansion Launchpad | South Korea serves as a blueprint for rapid adoption across Asia-Pacific, replicating the enterprise model in similar single-payer or regulated markets. | The Korean pilot achieves its projected $150K-$250K in annual recurring revenue and successfully expands to 10,000+ users [koreatechdesk.com, 2026]. | The company has "consistent interest from Korean insurers, digital health companies, and hospital innovation teams" and is using Korea as its "APAC launchpad" [koreatechdesk.com, 2026]. |
Compounding for Patientory would manifest as a classic network effect within its permissioned blockchain ecosystem. Each new enterprise customer (a hospital, insurer, or employer) onboarding to the PTOYMatrix adds more patient data nodes and validates the network's utility. This, in turn, increases the value of the data marketplace for life sciences companies seeking research cohorts, creating a revenue flywheel. Early evidence of this compounding is the platform's stated ability to integrate data from major EMR systems like Epic and Cerner [MM+M, 2018], a foundational step for network utility. Furthermore, the incentivized consumer app acts as a feeder, encouraging individual data contribution which enriches the enterprise analytics product, though this B2C2B flywheel is less proven than the enterprise-led motion.
Quantifying the size of the win requires looking at credible comparables. Public health data interoperability and analytics companies like Health Catalyst (NASDAQ: HCAT) have achieved market capitalizations in the hundreds of millions to billions of dollars, though their models differ. A more direct analog might be the acquisition multiples paid for health data platforms with network characteristics. If the "Enterprise SaaS Dominance" scenario plays out, capturing even a single-digit percentage of the U.S. self-insured employer market for population health tools,a multi-billion dollar segment,could support a valuation well into the hundreds of millions. This is a scenario-based outcome, not a forecast, but it frames the potential upside if Patientory's technology and compliance architecture become the preferred layer for consented health data exchange.
Data Accuracy: YELLOW -- Growth scenarios and expansion plans are cited from company blogs and regional tech press; the underlying pilot projections and business model pivot are reported but not independently verified by financial filings.
Sources
PUBLIC
[Dealroom.co, 2026] Patientory funding history | https://tracxn.com/d/companies/patientory/__pko-Au8XhBTUTqOBoXoB1SYhzh0CKqSEtSnzuX9ID8k/funding-and-investors
[Hypepotamus, 2026] Patientory business model pivot | https://hypepotamus.com/companies/patientory/
[World Economic Forum, 2022] Patientory organization profile | https://www.weforum.org/organizations/patientory/
[Halcyon] Chrissa McFarlane profile | https://halcyonhouse.org/fellows/chrissa-mcfarlane/
[koreatechdesk.com, 2026] Patientory South Korea expansion | https://www.koreatechdesk.com/patientory-south-korea-expansion/
[Patientory Blog, 2018] Chrissa McFarlane award | https://patientory.com/blog/2018/10/15/patientory-founder-wins-2018-medtech-insight-award
[MM+M, 2018] Chrissa McFarlane founding story | https://www.mmm-online.com/home/channel/people-on-the-move/patientory-founder-chrissa-mcfarlane-on-her-journey-from-jamaica-to-healthcare-entrepreneur/
[Crunchbase] Patientory company profile | https://www.crunchbase.com/organization/patientory-2
[LinkedIn] Patientory, Inc. LinkedIn page | https://www.linkedin.com/company/patientory
[StartUp Health, May 2021] Patientory video profile | https://www.youtube.com/watch?v=MO8A-A6bxk4
[PTOY.org] PTOYMatrix description | https://ptoy.org/
[PranaChain, 2025] Patientory blockchain network | https://pranachain.com/patientory-blockchain-health-data/
[HPN Online] Chrissa McFarlane HIMSS role | https://www.hpnonline.com/people/patientory-founder-chrissa-mcfarlane-named-co-chair-himss18-blockchain-workgroup
[MIT Solve, 2022] Patientory solution for equitable health systems | https://solve.mit.edu/challenges/equitable-health-systems/solutions/58486
[Patientory] Patientory website | https://patientory.com/
[businessmodelcanvastemplate.com, 2026] Patientory business model | https://businessmodelcanvastemplate.com/patientory-business-model-canvas/
[Instagram, 2024] CareGLP affiliate program | https://www.instagram.com/p/C6zXqKvOQ-7/
[Patientory, 2026] CareGLP weight management program | https://patientory.com/careglp
[Patientory Association, 2026] Neith Enterprise platform | https://patientoryassociation.org/neith-enterprise
[Grand View Research, 2022] Healthcare data analytics market size | https://www.grandviewresearch.com/industry-analysis/healthcare-data-analytics-market
[Global Market Insights, 2023] Clinical trial management software market size | https://www.gminsights.com/industry-analysis/clinical-trial-management-software-market
[Center for a Digital Future, 2023] Patientory data ownership profile | https://www.centerforadigitalfuture.org/blog/60kqfdgb4f8kljqy1j4ujvaqr1bx5y-364pg-bskhw-58gfs-c9t7w-xg5pd
[Tracxn, 2026] Patientory investors list | https://tracxn.com/d/companies/patientory/__pko-Au8XhBTUTqOBoXoB1SYhzh0CKqSEtSnzuX9ID8k
Articles about Patientory
- Patientory's Korean Pilot Anchors a $9.4 Million Bet on Data Sovereignty — The blockchain health data company, backed by Novartis and GSK, has pivoted to a compliance-first enterprise model with a live pilot projected to bring in $250,000 in annual revenue.